Panatuss Pediatric DXP Interactions
There are 569 drugs known to interact with Panatuss Pediatric DXP (dexbrompheniramine/dextromethorphan/phenylephrine), along with 8 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 94 are major, 471 are moderate, and 4 are minor.
- View all 569 medications that may interact with Panatuss Pediatric DXP
- View Panatuss Pediatric DXP alcohol/food interactions (2)
- View Panatuss Pediatric DXP disease interactions (8)
Most frequently checked interactions
View interaction reports for Panatuss Pediatric DXP (dexbrompheniramine / dextromethorphan / phenylephrine) and the medicines listed below.
- 5-HTP (5-hydroxytryptophan)
- allopurinol
- amitriptyline
- amlodipine
- ashwaganda
- astragalus
- atenolol
- bendroflumethiazide
- bisoprolol
- black cohosh
- candesartan
- celery
- cephalexin
- chlorthalidone
- clonidine
- colchicine
- CoQ10 (ubiquinone)
- Dermolate (hydrocortisone topical)
- diltiazem
- Estradiol Patch (estradiol)
- fluticasone nasal
- folic acid
- furosemide
- garlic
- Ginkgo Biloba (ginkgo)
- grape seed oil
- hawthorn
- indapamide
- L-Arginine (arginine)
- melatonin
Panatuss Pediatric DXP alcohol/food interactions
There are 2 alcohol/food interactions with Panatuss Pediatric DXP (dexbrompheniramine / dextromethorphan / phenylephrine).
Panatuss Pediatric DXP disease interactions
There are 8 disease interactions with Panatuss Pediatric DXP (dexbrompheniramine / dextromethorphan / phenylephrine) which include:
- cardiovascular disease
- anticholinergic effects
- asthma/COPD
- cardiovascular
- renal/liver disease
- BPH
- diabetes
- glaucoma
Report options
More about Panatuss Pediatric DXP (dexbrompheniramine / dextromethorphan / phenylephrine)
- Panatuss Pediatric DXP consumer information
- Compare alternatives
- Side effects
- Dosage information
- Drug class: upper respiratory combinations
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.